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Doxorubicin  (Dox)  has  been  used  for more  than  four  decades  to treat  cancer,  particularly  solid  tumours
and  haematological  malignancies.  However,  the  administration  of this  drug  is  a matter  of  concern  in
the  clinical  community,  since  Dox  therapy  is commonly  associated  with  dose-dependent  cardiotoxicity.
Attempts  at  alleviating  drug  generated  cardiac  damage  using  naturally  occurring  compounds  with  radical
scavenging  property  are  a promising  area  of research.  p-Coumaric  acid  (pCA)  is one  such  compound
which  has  signiﬁcant  antiradical  scavenging  effect.  This  study  aims  to investigate  the  effect  of  pre and
co-administration  of  pCA  on mitigating  or  preventing  Dox  induced  cardiotoxicity  in vitro  using H9c2
cardiomyoblast  cell lines.  Addition  of  pCA and  Dox  were  performed  for both treatment  and  control  sets
on H9c2  cells.  Sulphorhodamine  B assay  was  used  to  study  the  cytotoxic  effect  of  pCA and  Dox.  The
effect  of the  drug  on  cell  morphology,  cell  viability  and  nuclear  damage  was  studied  using  AO/EB  and
DAPI  staining.  ROS  production  was  studied  using  DCFH-DA  staining.  Mitochondrial  membrane  potential
and  intracellular  calcium  levels  were  assessed  by  rhodamine  123  and  Fura  2AM  staining.  pCA showed
strong  ABTS  cation  radical  scavenging  activity  and  FRAP  activity  in a dose  dependent  manner.  The  results
showed  that  Dox  has  signiﬁcant  cytotoxic  effect  in  a  dose  dependent  manner  while  pCA, even  at higher
concentrations  did  not  display  any  signiﬁcant  cytotoxicity  on H9c2  cells.  Both  pre  treatment  and  co-
administration  of pCA reduced  the  drug  induced  toxic  effects  on  cell  morphology  and  enhanced  the
number  of  viable  cells  in comparison  to  the  Dox  treated  cells  as  evident  from  the AO/EB  and  DAPI staining
images.  The  Dox  induced  ROS production  was  found  to  be  signiﬁcantly  reduced  in pCA pre-treated  and  co-
administered  cells.  Dox  induced  changes  in  mitochondrial  membrane  potential  and  intracellular  calcium
levels  were  remarkably  improved  following  pre  and  co-treatment  of H9c2  cells  with  pCA.  These  results
clearly  suggest  that pre-treatment  and co-administration  of  pCA is a promising  therapeutic  intervention
in  managing  Dox  mediated  cardiotoxicity.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Doxorubicin (Dox) is an anthracycline antibiotic effective in the
reatment of solid tumours and haematological malignancies [1].
his drug is commonly used as part of a combination regimen in
oth paediatric and adult patients. However, administration of Dox
s a matter of concern in the clinical community since anthracycline
Abbreviations: DMEM, Dulbecco’s modiﬁed Eagle’s medium; FBS, foetal bovine
erum; DAPI, trypan blue, 4′ ,6-diamidino-2-phenylindole; pCA, p-coumaric acid;
RB, sulphorhodamine-B; DCFH-DA, dichloroﬂuorescin diacetate; ROS, reactive
xygen species; Dox, doxorubicin; ABTS, 2,2′-azinobis-(3-ethylbenzothiazoline-6-
ulfonic acid); RNS, reactive nitrogen species.
∗ Corresponding author.
E-mail address: nevinkg@gmail.com (K.G. Nevin).
1 Both the authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.toxrep.2015.08.002
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
therapy is commonly associated with dose-dependent cardiotoxic-
ity [2]. Though the exact mechanism of cardiotoxicity is not yet fully
understood, Dox evidently induced membrane alterations through
lipid peroxidation, free radical generation, increased myocardial
levesl of sodium and calcium, impaired myocardial DNA and RNA
synthesis and induced apoptosis on cardiomyocytes [3–6]. Drug
induced toxicity is a multifactorial process and one of the most com-
mon  causes attributed to this is the generation of reactive oxygen
species (ROS)/nitrogen species (RNS) as a result of drug redox recy-
cling. It has therefore been suggested that some phytochemicals
with high antioxidant potential, when administered together with
antitumour agents, could decrease/attenuate the toxic side effects
of chemotherapy induced as a byproduct of oxidative stress and
thus reduce the risk of heart failure [7]. Attempts are progressing
to alleviate drug generated ROS induced damage, using naturally
occurring compounds with radical scavenging property. Naturally
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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◦ig. 1. Chemical structure of p-coumaric acid [3-(4-hydroxyphenyl)-2-propenoic
cid].
ccurring antioxidant compounds such as naringenin, probucol,
esveratrol, epigallocatechin gallate and quercetin have been tried
nd tested with promising results with regards to their effect on
ox induced toxicity in in vitro studies as well as in animal models
8–12]. p-Coumaric acid (pCA), a hydroxy derivative of cinnamic
cid (Fig. 1) can be found in a wide variety of edible plants such
s peanuts, barley grains, navy beans, tomatoes, carrots, garlic and
oney. It is also present in wine and vinegar in signiﬁcant amounts
13–15]. pCA is one of the many phenolic compounds which is con-
umed on a daily basis by a majority of the population worldwide
hrough their routine dietary intake. pCA is also reported to have
ntioxidant properties and is believed to reduce the risk of stom-
ch cancer by reducing the formation of carcinogenic nitrosamines
16,17]. Though pCA possess anticancer activity, the cardioprotec-
ive effect of the phenol has not been studied progressively. This
tudy was designed to evaluate the beneﬁcial effect of pCA on Dox
nduced toxicity in rat-derived cardiomyoblast cell lines in in vitro
onditions.
. Materials and methods
.1. Chemicals
Dulbecco’s modiﬁed Eagle’s medium (DMEM), foetal bovine
erum (FBS) and other cell culture reagents were procured from
i-Media Laboratories. Acridine orange (AO), ethidium bromide
EB), trypan blue, 4′,6-diamidino-2-phenylindole dihydrochloride
DAPI) and rhodamine-123(R-123) were obtained from Hi-Media
aboratories, India. Doxorubicin hydrochloride, p-coumaric acid,
ulphorhodamine-B (SRB), dichloroﬂuorescin diacetate (DCFH-DA)
nd 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)
ere purchased from Sigma–Aldrich, USA. Fura-2 acetoxymethyl
ster (Fura-2AM) was purchased from Invitrogen.
.2. ABTS cation free radical-scavenging activity
Free radical scavenging ability of pCA in terms of ABTS+ radi-
al scavenging activity was  evaluated by the procedure of Re et al.
18], with some minor modiﬁcations. ABTS which is a colourless
ompound is converted to its blue–green counterpart ABTS+ by the
oss of an electron by nitrogen on the parent compound. ABTS+ was
enerated by reacting ABTS stock solution with 2.45 mM potassium
ersulfate and allowing the mixture to stand in the dark at room
emperature for 12–16 h prior to use. Different concentrations of
CA (0.04–152 M)  were allowed to react with 180 L of ABTS+
olution for 12 min  under dark conditions at room temperature.
he absorbance of the sample was measured at 734 nm.  Butylated
ydroxyl toluene (BHT) was used as positive control. The activity
as expressed as percentage of ABTS+ radical scavenging calculated
y the following formula:
BTS+scavenging activity(%)  = [ (Ac − At) × 100],
(Ac)
here Ac is the absorbance value of the control and At is the
bsorbance value of the test samples.ports 2 (2015) 1213–1221
2.3. Ferric-reducing/antioxidant power (FRAP) assay
The FRAP assay was  carried out by the method described by
Benzie and Strain [19]. This method is based on the principle of
reduction of Fe3+-TPTZ (2,4,6-tripyridyl-s-triazine) to Fe2+ TPTZ
complex at a low pH which gives purple–blue colour measured at
595 nm.  Brieﬂy, different concentrations of pCA (0.04–152 M)  was
mixed with 180 L of FRAP reagent (300 mM acetate buffer pH 3.6,
10 mM TPTZ in 40 mM HCl and 20 mM FeCl3·6H2O in the volume
ratio 10:1:1) on a 96 well plate. Mixture was allowed to stand for
6 min  and absorbance of samples was measured at 595 nm.  Ascor-
bic acid and FeSO4 were used as reference standards. An increase in
absorbance was considered as an indicator of a higher antioxidant
potential.
2.4. Cell culture
H9c2 myoblast cells derived from the rat myocardium was
obtained from National Centre for Cell Sciences (NCCS), Pune, India.
The myoblast cells were cultured in Dulbecco’s modiﬁed Eagle’s
Medium (DMEM) medium supplemented with 10% FBS and 10 ml/l
100 × antibiotic–antimycotic solution containing 10,000 units of
penicillin and 10 mg/ml  streptomycin in 0.9% normal saline in a
humidiﬁed atmosphere of 95% air and 5% CO2 at 37 ◦C.
2.5. Cytotoxicity analysis
Cytotoxicity of different concentrations of pCA and Dox was
evaluated individually using the sulphorhodamine B assay (SRB).
SRB is a bright pink aminoxanthene dye which binds to proteins
electrostatically under mildly acidic conditions. The ﬁxed dye,
measured photometrically after solubilisation correlates with total
protein synthesis rates and thereby with cell proliferation [20]. To
determine and standardise the concentration of pCA and Dox  to
be used in further experiments, H9c2 cells (2 × 104 cells/well in 96
well plates) were seeded with DMEM medium and incubated for
48 h at 37 ◦C with 95% air and 5% CO2 to allow the cells to become
semi conﬂuent (70–80%). Adhered cells were then treated with dif-
ferent concentrations of pCA (24–760 M)  and Dox (0.1–13 M)
individually for 72 h. After the experimental period, cell ﬁxation
was carried out by the addition of 50% ice-cold trichloroacetic acid
(TCA). Plates were then incubated at 4 ◦C for 30 min  and the plates
were then rinsed 4-5 times under running tap water. Plates were
air-dried and 50 L of SRB solution (0.4% in 1% acetic acid) was
added to each well and incubated for 20 min  at room temperature.
At the end of the staining period the plates were washed with 1%
acetic acid to remove the unbound dye and bound dye was solu-
bilised by the addition of 10 mM  Tris base (pH 10.5). Absorbance
was measured at 490 nm on a Thermoscientiﬁc Varioskan Flash
Microplate Reader. IC50 values were calculated by plotting the OD
readings versus the drug concentrations. Percentage cell death was
calculated by the following formula.
% Cell death = ODControl − ODTest
ODControl
× 100
2.6. Cytotoxicity of pre and co-administration of pCA with Dox
To determine the cytotoxicity and morphological changes dur-
ing pre and co-administration of pCA and Dox, H9c2 cells (2 × 104
cells/well in 96-well plates) were seeded with DMEM medium and
incubated for 48 h at 37 C with 95% air and 5% CO2 to allow the cells
to become semi-conﬂuent. After this period the cells were pre/co-
treated with pCA (380 M)  and Dox (1.5 Dox M)  respectively, for
72 h. After the incubation period, the cytotoxicity was  measured
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sing SRB assay as described earlier. Morphological changes were
valuated using a phase contrast microscope.
.7. Acridine orange/Ethidium bromide (AO/EB) staining
To evaluate if pCA has a protective effect on Dox induced apo-
tosis, a ﬂuorescent double-staining method involving AO/EB was
mployed. H9c2 cells (8 × 104 cells/well in 24-well plates) were
eeded in DMEM medium and incubated for 48 h at 37 ◦C with 95%
ir and 5% CO2 to allow the cells to become semi-conﬂuent. After
his period the cells were pre/co-treated with pCA (380 M)  and
ox (1.5 Dox M)  respectively, for 24 h. After 24 h, adhered cells
ere rinsed in PBS (pH 7.4) and a 1:1 solution of AO (100 g/ml)/EB
100 g/ml) was added to the treated wells. The plates were incu-
ated in the dark at 37 ◦C for 30 min. Each well was examined under
 ﬂuorescence microscope with a FITC ﬁlter at 20× magniﬁcation
o determine the live and dead cells [21].
.8. DAPI staining
DAPI staining was done to detect the changes in nuclear mor-
hology and DNA damage during treatment with pCA and Dox.
9c2 cells (8 × 104 cells/well in 24-well plates) were seeded in
MEM medium and incubated for 48 h at 37 ◦C with 95% air and
% CO2 to allow the cells to become semi-conﬂuent. Semi conﬂu-
nt cells were then pre/co-administered with pCA (380 M)  and
ox (1.5 Dox M)  respectively, for 24 h. Following the treatment
eriod, adherent cells were rinsed thrice in PBS to completely
emove traces of the growth medium. Cells were then ﬁxed for
0 min  in 3.7% formaldehyde and again rinsed thrice in PBS prior
o permeabilisation in 0.2% Triton-X-100 for 5 min. Cells were then
ashed and incubated with DAPI labelling solution for 5 min  in the
ark. The labelling solution was then aspirated off and stained cells
ere rinsed thrice in PBS and changes in the nuclear morphology
nd DNA damage was observed using a ﬂuorescence microscope
Olympus) with the DAPI ﬁlter at 20× magniﬁcation [22].
.9. DCFH-DA staining
Intracellular ROS levels were measured using a cell permeable
uorescent probe 2′,7′-dichloroﬂuorescin diacetate (DCFH-DA).
CFH-DA diffuses through the cell membrane where it is
ydrolysed by an intracellular esterase to the non-ﬂuorescent
ichloroﬂuorescin (DCFH) which is rapidly oxidised by ROS to ﬂuo-
escent dichloroﬂuoresin. H9c2 cells (8 × 104 cells/well in 24-well
lates) were seeded in DMEM medium and incubated for 48 h
t 37 ◦C with 95% air and 5% CO2 to allow the cells to become
emi-conﬂuent. Semi-conﬂuent H9c2 cells were treated with pCA
380 M)  and Dox (1.5 Dox M)  for 6 h. After the treatment period,
CFH-DA (in absolute DMSO) was added to treated plates at a
nal concentration of 10 M and incubated in the dark at 37 ◦C
or 30 min. Post-staining, plates were rinsed twice with PBS and
mages were taken on a ﬂuorescent microscope (Olympus) using
he appropriate bandpass FITC ﬁlter and relative ﬂuorescence was
easured using ImageJ 1.48 software [23].
.10. Determination of mitochondrial membrane potential
MMP;  m)
To determine the effect of pCA on the electrical potential across
he inner mitochondrial membrane of Dox treated H9c2 cells, Rho-
amine 123 (R-123), a lipophilic,cationic indicator was used. H9c2
ells (2 × 104 cells/well in 96-well plates) were seeded in DMEM
edium and incubated for 48-hours at 37 ◦C with 95% air and
% CO2 to allow the cells to become semi- conﬂuent. After this
eriod cells were pre/co-administered with pCA (380 M)  and Doxports 2 (2015) 1213–1221 1215
(1.5 M Dox) respectively, for 24 h. Cells were then rinsed with PBS
and fresh media containing R-123 solution (10 g/ml) was  added to
treated wells and the plates were incubated in the dark at 37 ◦C for
20–30 min. Subsequently, the cells were washed twice with PBS
and the cell images were taken using a ﬂuorescence microscope
(Olympus 1 × 51) [24].
2.11. Measurement of the intracellular calcium levels
Alterations in intracellular calcium levels were evaluated using
the ratiometric probe FURA-2-AM. H9c2 cells (2 × 104 cells/well)
were pre/co-treated with pCA (380 M)  and Dox (1.5 M Dox)
respectively, for 24 h. After the treatment period, culture medium
in the wells was replaced with Krebs buffer (1 mM CaCl2; 132 mM
NaCl; 4 mM KCl; 1.2 mM Na2HPO4; 1.4 mM MgCl2; 6 mM Glucose;
10 mM HEPES, pH 7.4), supplemented with 1 mg/ml  bovine serum
albumin (BSA) and 5 M FURA-2AM, and incubated at 37 ◦C in the
dark for 40 min. Cells were rinsed twice with Kreb’s buffer fol-
lowing the incubation period and fresh buffer supplemented with
BSA minus the probe was added to the wells. The cells were then
observed by ﬂuorescence microscopy using the appropriate band-
pass ﬁlter. (Olympus 1 × 51) [25].
2.12. Statistical analysis
Experimental results are expressed as mean ± S.D of three
independent experiments. One-way ANOVA using SPSS-19,IBM
Technologies Software was used for statistical analysis, followed
by Duncan’s multiple comparison test to assess the signiﬁcance
between groups. Value of p < 0.05 was  considered to be statistically
signiﬁcant.
3. Results
3.1. Radical scavenging activity of pCA
The total antioxidant capacity of different concentrations of pCA
was calculated from the decolourisation of ABTS*+, which was  mea-
sured spectrophotometrically at 734 nm.  Interactions of the dye
with pCA reduced the absorbance values of the radical cation and
the results obtained have been expressed as percentage inhibi-
tion in comparison to the controls. The results showed pCA to
have strong ABTS radical scavenging activity in a concentration
dependent manner (Fig. 2A). Fig. 2B shows the FRAP activity for
different concentrations of pCA. FRAP assay is a simple inexpensive
method to evaluate the total antioxidant potential of plant compo-
nents. Higher the FRAP value obtained, greater is the antioxidant
power of the compound. Our results showed that FRAP activity
increased with higher concentrations of pCA. Concentrations of pCA
from 0.04–9.5 M showed a lower FRAP activity; while 38.1 M
and 152 M showed a higher antioxidant potential. The aforemen-
tioned concentrations (38.1 and 152 M)  also showed a 100% ABTS
scavenging activity when tested.
3.2. Cell viability after exposure to different concentrations of Dox
and pCA alone
The viability of H9c2 cardiomyoblast cells was  evaluated after
72 h of exposure to different concentrations of DOX  and pCA by SRB
method. As shown in Fig. 3A, Dox treatment induced signiﬁcant
cytotoxicity in a dose dependent manner. The IC50 value was found
to be 1.5 M.  This concentration was found to be ideal through ini-
tial AO/EB staining and was set as the working drug concentration
for all further experiments related to drug studies. We  examined
the effect of different concentrations of pCA on H9c2 cell viability
to select a concentration of pCA which is both non-toxic to cells as
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Fig. 2. Graphical presentation on the effect of different concentrations of pCA on in vitro ABTS scavenging and FRAP activity. (A) ABTS scavenging activity, (B) FRAP activity.
The  values are expressed as ±S.D. of three separate experiments.
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f  Dox; (B) different concentrations of pCA. *Signiﬁcant compared to control (p < 0.0
ell as effective in preventing/improving Dox induced cytotoxic-
ty. The cells were incubated with pCA at different concentrations
23–760 M)  for 72 h. The percentage of cell viability under dif-
erent treatment conditions has been shown in Fig. 3B. The results
learly showed that pCA was not cytotoxic towards the relevant cell
ine at tested concentrations. 380 M and 761 M pCA displayed a
ower range of cytotoxicity, which was not prominent in compar-
son to Dox treatment. Since the cytotoxicity was at a negligibly
ower range, the concentration—380 M,  with higher free radical
cavenging activity (results not shown) was used for the further
tudies in conjunction with Dox.
.3. pCA reduces Dox induced cytotoxicity
Fig. 4 shows the effect of pre-treatment and co-administration of
CA on Dox induced cytotoxicity in H9c2 cell lines. Dox treatment at
 concentration of 1.5 M showed signiﬁcant cytotoxicity. The cell
iability was found to be 43% after 72 h. The results shown indicate
hat both pre and co-administration of pCA signiﬁcantly reduced
he cell toxicity induced by Dox. Pre-treatment of pCA helped to
etain 86% cell viability and co-administration of pCA helped to
etain the cell viability at 84% (Fig. 4, panel F). Morphological anal-
sis showed that Dox treatment induced severe structural changes
o H9c2 cells. Most of the cells appeared to be rounded off, los-
ng their adherent property following drug treatment. (Fig. 4, panel
). Treatment of cells with pCA did not show any signiﬁcant struc-
ural changes/damages to the regular cell morphology (Fig. 4, panel
). Both pre and co-administration of pCA prevented the structural
hanges induced by Dox on H9c2 cells (Fig. 4, panels D,E)..4. pCA inhibits Dox induced apoptosis in H9c2 cells
Since Dox decreased cell viability and affected cell size, it was
ypothesised that apoptosis might be involved in the reduction ofs are expressed as ±SD of three individual experiments. (A) Different concentrations
cell viability induced by Dox. When the treated and control cells
were stained with the DNA-binding dye DAPI, the cell morphology
of treated cells revealed nuclei with condensed chromatin and frag-
mented nuclei, which are characteristics of apoptotic cells (Fig. 5,
panel G). When the H9c2 cells were exposed to 1.5 M Dox for 24 h,
the total number of viable cells and the size of most cells reduced
noticeably. Shrunken/swollen cytoplasm and nuclei pyknosis could
also be observed. Pre treatment and co-administration of pCA
showed signiﬁcant reduction in these properties induced by Dox
(Fig. 5, panels I,J). AO/EB staining revealed that exposure to 1.5 M
Dox reduced the viability of the cells and the stained cells appeared
to be red in colour, characteristic of non-viable cells. (Fig. 5, panel
B). Treatment with pCA did not show any red coloured cells which
is indicative of the non-cytotoxic nature of the compound (Fig. 5,
panel C). Pre treatment and co-administration of pCA showed sig-
niﬁcant reduction in the numbers of non-viable compared to the
cells treated with 1.5 M Dox alone (Fig. 5, panels D,E).
3.5. pCA modulates ROS production in H9c2 cells
Fig. 6 shows the effect of ROS production in Dox and pCA treated
cells. Treatment with 1.5 M Dox showed signiﬁcant increase in
ROS production as indicated by a 2-fold increase in DCF ﬂuores-
cence (Fig. 6, panels C,F). Cells treated with pCA alone showed DCF
ﬂuorescence at normal levels (Fig. 6, panels C,F). Cells pretreated
and/ cotreated with pCA followed by Dox showed a signiﬁcant
reduction in ROS production as evident from a 1.3 and 1.5 fold
reduction in DCF ﬂuorescence as compared to cells treated with
Dox alone (Fig. 6, panels D–F).3.6. pCA modulates MMP in H9c2 cells exposed to Dox
Fig. 7 shows the variations in mitochondrial membrane poten-
tial in Dox and pCA treated cells. Treatment with 1.5 M Dox
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Fig. 4. Cytotoxic effect of pre and co-administration of pCA and Dox on H9c2 cells. Values are expressed as ±SD of three individual experiments. Typical morphological changes
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o  administration, pCA + Dox indicates pre treatment. *Signiﬁcant compared to con
f  three separate experiments.
howed a signiﬁcant decrease in MMP  as indicated by signiﬁcant
eduction in R-123 ﬂuorescence as shown (panel B). Cells treated
ith pCA alone showed a normal MMP  (panel C). Pre and co-
dministration of pCA showed a signiﬁcant restoration of MMP  as
vident from the higher ﬂuorescence in comparison to exclusively
ox treated cells (panels D,E).
.7. pCA modulates intra cellular Ca2+ production in Dox treated
9c2 cells
Fig. 8 shows the effects of treatment with Dox and pCA intra-
ellular Ca2+ levels in cells. Treatment with 1.5 M Dox showed a
igniﬁcant increase in Ca2+ production as indicated by increase in
uorescence within cells (panel B). Cells treated with pCA alone dis-
layed ﬂuorescence at levels identical to the control cells (panels
 and A). Pre and co-administration of pCA showed a signiﬁ-
ant mobilisation of intracellular Ca2+ as evident from the lowerdicates the % cell viability of control, Dox and pCA treated cells, Dox + pCA indicates
 < 0.05), **signiﬁcant compared to Dox (p < 0.05). The picture is the representation
ﬂuorescence when compared to cells treated with Dox alone (pan-
els D and E).
4. Discussion
Doxorubicin (Dox) is a powerful and effective drug used to treat
a multitude of human neoplasm’s including solid tumours. Though
the drug is highly sought after for its remarkable anti-cancer effects,
its clinical use is limited by severe cardiotoxic side effects. There are
several mechanisms proposed for the cardiotoxic effects of Dox of
which one major mechanism behind drug toxicity has been proved
to be the excessive generation of ROS. The quinone moiety of Dox is
converted enzymatically or non-enzymatically by cytochrome P450
into its semiquinone form by the acquisition of one electron. This
semiquinone form is then oxidised by molecular oxygen to yield
Dox (recycling) in its quinone form with a concomitant production
of superoxide radicals [26]. Generated radicals are either scav-
enged by the dismutase enzymes spontaneously or at a slower rate
1218 S.M. Chacko et al. / Toxicology Reports 2 (2015) 1213–1221
Fig. 5. Apoptotic analysis using AO/EB and DAPI staining on H9c2 cells treated pCA, dox and pre/co-administration of pCA after 24 h of treatment. The images were taken using
ﬂuorescent microscope (magniﬁcation 20×). (A) Control, (B) Dox (1.5 M), (C) pCA (380 M),  (D) pCA (380 M) + Dox (1.5 M)  co-administration. (E) Pre pCA (380 M)  + Dox
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roducing H2O2 leading to cardiac toxicity [27]. Free radicals are
enerated continuously in the human body due to metabolism and
iseases [28]. Oxidative damage, which causes extensive damage
o tissues and biomolecules leading to various disease conditions,
an be overcome using many synthetic drugs which are associated
ith severe adverse side effects. An alternative suggestion would
equire one to consume natural antioxidants from food and tradi-
ional medicine [29,30].
Due to the importance of Dox in chemotherapy, researchers
round the world have put in great efforts to reduce its toxic
ide effects. The commonly employed strategies involve the use
f drug analogues or combination therapy, which has proved to
e unfruitful [31]. Presently, studies are progressing in a manner
o as to isolate low toxic components from natural sources, which
osses a signiﬁcant free radical scavenging activity, that can be used
long with Dox to prevent the severity of cardiotoxicity. p-coumaric
cid (pCA), is a phenolic acid widely distributed in plants and one
hich forms an important constituent of the human diet worldwide
32]. Phenolic acids are capable of binding metal ions, scaveng-
ng reactive oxygen species (ROS), reactive nitrogen species (RNS),
pregulating the endogenous antioxidant systems and preventing
he oxidative damages to biomolecules [33]. Though previous stud-
es showed that pCA alone or in combination with other natural
roducts can modulate the lipid peroxidation levels in Dox treated
ats [34,35], the effect of pCA on cardiomyoblasts have not been
tudied yet. This study was  designed to evaluate the effect of pCA
n H9c2 cardiomyoblast in in vitro conditions.
It was found that different concentrations of Dox (0.1–13 M)
howed a signiﬁcant cytotoxicity on cardiomyoblasts in a dose
ependent manner (Fig. 3), while different concentrations of pCA
24-760 M)  did not show cytotoxicity towards H9c2 cells. We
etermined the ideal concentration of pCA as 380 M and that of
ox as 1.5 M to study the protective effect of pCA on Dox treated
ells. Dox treatment is more toxic to undifferentiated muscle cells,
ontributing to impaired cardiac development and toxicity persis-
ence. H9c2 myoblasts, a rat embryonic cell line, which has the
bility to differentiate into a skeletal or cardiac muscle phenotype,
an be instrumental in understanding DOX cytotoxicity [36].
To determine the effect of Dox and pCA on H9c2 morphol-
gy, cells were treated with Dox (1.5 M)  and pCA (380 M)  for
2 h and photographs were taken using a phase contrast micro-
cope (Fig. 4). The data showed that cell density was  signiﬁcantly
ecreased on Dox treatment with concomitant loss of their adher-
nt nature and appeared to be rounded indicating progressive cellted with doxorubicin displaying morphological changes such as fragmented nuclei
distorted nuclei of varying nuclear shape and size (white arrows) in comparison to
death. While cells pre/co-administered with Dox and pCA showed
signiﬁcant cell density with normal morphology. Previous studies
showed that H9c2 cell when exposed to lower concentrations of
Dox causes alterations in ﬁbrous structural proteins including the
nuclear lamina and sarcomeric cardiac myosin, as well as mito-
chondrial depolarisation and fragmentation, membrane blebbing
with cell shape changes, and phosphatidylserine externalisation.
At higher concentrations, more profound alterations are evident,
including nuclear swelling with disruption of nuclear membrane
structure, mitochondrial swelling, and extensive cytoplasm vac-
uolisation [37].
The cell lines treated with Dox and pCA was also stained with
AO/EB and DAPI to determine the apoptotic effect. Results clearly
showed that the cells treated with Dox undergo loss of cell viability
as indicated by the presence of a large amount of red coloured cells
in comparison to the control. Cells pre/co-administered with Dox
and pCA showed signiﬁcant reduction in dying cells as indicated
by the lower number of red coloured cells. There are numerous
evidences suggesting that cardio myocytes undergo apoptosis fol-
lowing Dox treatment both in vivo and in vitro, indicating that
apoptosis is the main mechanism leading to Dox mediated car-
diac dysfunction [38,39]. It was earlier reported that pCA, through
its strong antioxidant character exerts a protective effect on the
alterations in gene-expression proﬁle in sodium arsenite induced
cardiotoxicity in rats [40]. pCA also protected isoproterenol induced
myocardial apoptosis by inhibiting oxidative stress in Wistar rats.
The protective effects of pCA as observed in the previous studies
were attributed to its anti-lipid peroxidative, anti- apoptotic and
antioxidant properties. pCA also increased the myocardial expres-
sion of Bax, caspase-8, caspase-9 and Fas genes and showed a
decrease in the myocardial expression of Bcl-2 and Bcl-xL genes
[41].
To evaluate whether the protective effect of pCA is dependent
on the reduction of ROS in mitochondria, the cells were stained
with DCFH-DA after 6 h of treatment. The results showed that Dox
treatment signiﬁcantly induced ROS formation in cells as evidenced
from the higher ﬂuorescent intensity, while cells treated with pCA
in the pre and co-administration mode with Dox showed reduced
levels of ROS levels in comparison to the Dox treated cells. pCA sig-
niﬁcantly reduced the ROS formation in H9c2 cells, which may be
partly due to the ability of pCA to quench the free radicals initiated
by Dox. Dox induces an iron-mediated increase in ROS and cellular
damage by futile redox cycling [42]. This redox cycle in the presence
of heavy metals, such as iron leads to the formation of superoxide,
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Fig. 6. Analysis of ROS formation using DCFH-DA staining on H9c2 cells treated pCA, dox and pre/co-administration of pCA after 6 h of treatment. The images were taken
u pCA (3
p escent
*  0.05)
w
t
r
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c
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p
i
s
psing  light (magniﬁcation 20×). (A) Control, (B) Dox (1.5 M)  (C) pCA (380 M), (D) 
icture is the representation of three separate experiments. F shows the mean ﬂuor
*signiﬁcant compared to Dox (p < 0.05), #signiﬁcant compared to pCA and Dox (p <
hich is converted to H2O2 spontaneously or by superoxide dismu-
ase. Subsequently, H2O2 may  be converted to highly toxic hydroxyl
adicals leading to cardiomyopathy [43–45].
The molecular mechanisms of doxorubicin induced mitochon-
rial injury in cardiac muscle cells are largely unclear [46]. Dox
auses DNA damage and formation of reactive oxygen species,
ventually resulting in apoptosis. The dissipation of membrane
otential () is one of the markers for mitochondrial involvement
n apoptosis [47]. In the present study, we set up Rhodamine-123
taining experiment to assess the therapeutic potential of pCA in
reventing the dissipation of  in doxorubicin-induced apoptosis80 M) + Dox (1.5 M) co-administration, (E) pre pCA(380 M)  + Dox  (1.5 M).  The
 intensity of control and treated groups. *Signiﬁcant compared to control (p < 0.05),
.
in H9c2 cells. It was  found that pCA prevented the reduction of 
when pre/co administered with Dox.
Dox-induced cardiotoxicity is also characterised by an increase
in intracellular calcium levels. Dysregulation of intracellular cal-
cium concentrations is both a result and a cause of ROS-generation
[48]. The ROS and H2O2 generated by these mechanisms alter
normal calcium homeostasis in a variety of muscle cell types via
disruption of normal sarcoplasmic reticulum function [49]. The
decrease in ROS production and intracellular calcium levels in pCA
treated H9c2 cells indicate that the protective effect of this com-
pound is mediated through mitochondria.
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Fig. 7. Analysis of mitochondrial membrane potential using rhodamine 123 in H9c2 cells treated pCA, dox and pre/co-administration of pCA after 24 h of treatment. The
images were taken using light (magniﬁcation 20×). (A) Control, (B) Dox (1.5 M)  (C) pCA (380 M), (D) pCA (380 M) + Dox (1.5 M)  co administration, (E) pre treatment of
pCA  (380 M)  + Dox (1.5 M). The picture is the representation of three separate experiments.
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iig. 8. Intracellular calcium analysis levels determined using FURA-2/AM in H9c2 ce
ere  taken using ﬂuourescent microscope (magniﬁcation 20×). (A) Control, (B) Dox
reatment of pCA (380 M)  + Dox (1.5 M).  The picture is the representation of thre
Results from the present study suggest that pCA is capable of
educing the toxic effect induced by Dox in H9c2 cell lines, which
ay  be due to the reduced drug metabolism, down regulation of
ro-apoptotic molecules as well as reduction in oxidative stress by
reventing ROS formation mediated through the inhibition of Fe-
ox complex formation. Further work at proteomic and genomic
evels could give one more insight into the precise molecular targets
y which pCA exerts its protective effects on Dox induced toxicity.. Conclusion
In summary, this study provides evidence showing that Dox
nduced cardiomyoblast toxicity is partly mediated by mitochon-ated pCA, dox and pre/co-administration of pCA after 24 h of treatment. The images
M)  (C) pCA (380 M),  (D) pCA (380 M) + Dox (1.5 M)  co-administration, (E) pre
rate experiments.
drial ROS production. pCA, with its potent antioxidant potential,
attenuates ROS-induced cardiomyoblast damage when pre-treated
or co-treated with Dox.
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